Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
49 hedge funds and large institutions have $183M invested in Inozyme Pharma in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 5 closing their positions.
504% more capital invested
Capital invested by funds: $30.4M → $183M (+$153M)
260% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 5
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
32% more funds holding
Funds holding: 37 → 49 (+12)
1.5% more ownership
Funds ownership: 71.66% → 73.16% (+1.5%)
56% less call options, than puts
Call options by funds: $166K | Put options by funds: $378K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.68M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.08M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.86M |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$2.85M |
| 2 |
CA
CHI Advisors
New York
|
-$2.28M |
| 3 |
Renaissance Technologies
New York
|
-$192K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$42.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.5K |
INZY Hedge Fund Activity: Q1 2023 in Review
49 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2023, worth a combined $183M — up 504% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new INZY positions and 5 closed out — a net gain of 12 holders — while 18 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.68M. The largest seller was VR Adviser, exiting entirely with an estimated $2.85M sold.
- 49 institutional investors held Inozyme Pharma (INZY) as of Q1 2023, up from 37 in Q4 2022.
- Funds reported $183M of Inozyme Pharma stock for Q1 2023, up 504% quarter-over-quarter.
- 17 funds opened new Inozyme Pharma positions in Q1 2023 and 5 closed out, a net change of +12 holders.
- The largest Inozyme Pharma buyer in Q1 2023 was Millennium Management, an estimated $3.68M added.
- The largest Inozyme Pharma seller in Q1 2023 was VR Adviser, an estimated $2.85M sold.
Based on aggregated 13F filings for Q1 2023.